JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

Начало・Списък с акции・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

64.65 -4.65

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.88

Максимум

69.43

Ключови измерители
By Trading Economics
Приходи	155M -24M
Продажби	229M 256M
Марж на печалбата	-9.26
Служители	711
EBITDA	-546M -148M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+13.67% upside

Дивиденти
By Dow Jones
Следващи печалби	5.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.1B 10B
Предишно отваряне	69.3
Предишно затваряне	64.65

Настроения в новините

By Acuity

15%

85%

15 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

11.5 / 12.23 Подкрепа & съпротива

Arrowhead Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.02.2026 г., 00:00 ч. UTC

Горещи акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4.02.2026 г., 22:55 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4.02.2026 г., 21:44 ч. UTC

Печалби

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4.02.2026 г., 21:39 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5.02.2026 г., 00:00 ч. UTC

Печалби

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5.02.2026 г., 00:00 ч. UTC

Печалби

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4.02.2026 г., 23:45 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4.02.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4.02.2026 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4.02.2026 г., 22:30 ч. UTC

Печалби

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4.02.2026 г., 22:30 ч. UTC

Печалби

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4.02.2026 г., 22:21 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4.02.2026 г., 22:15 ч. UTC

Пазарно говорене

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4.02.2026 г., 22:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

4.02.2026 г., 21:53 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4.02.2026 г., 21:51 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.02.2026 г., 21:45 ч. UTC

Печалби

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4.02.2026 г., 21:44 ч. UTC

Печалби

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4.02.2026 г., 21:43 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4.02.2026 г., 21:41 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 21:36 ч. UTC

Пазарно говорене

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Сравнение с други в отрасъла

Ценова промяна

Arrowhead Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

13.67% нагоре

12-месечна прогноза

Среден 82 USD 13.67%

Висок 110 USD

Нисък 35 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Arrowhead Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Arrowhead Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

11.5 / 12.23Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

15 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.